| P2093 | author name string | Changsu Han | |
| | Chi-Un Pae | |
| | Sheng-Min Wang | |
| P2860 | cites work | Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration | Q21092366 |
| | A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression | Q24630153 |
| | Triple reuptake inhibitors: the next generation of antidepressants | Q24658248 |
| | Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy | Q27024227 |
| | A review of current evidence for acetyl-l-carnitine in the treatment of depression | Q28235560 |
| | Current investigational drugs for major depression | Q28244223 |
| | Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants | Q28472408 |
| | Triple Reuptake Inhibitors: A Premise and Promise | Q28972234 |
| | Antidepressant effects of ketamine in depressed patients | Q29617327 |
| | A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression | Q29617914 |
| | Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy | Q30468153 |
| | Monoamine neurocircuitry in depression and strategies for new treatments | Q30619239 |
| | Glucocorticoid prevents brain-derived neurotrophic factor-mediated maturation of synaptic function in developing hippocampal neurons through reduction in the activity of mitogen-activated protein kinase. | Q33643252 |
| | Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data | Q33676260 |
| | Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data | Q33799660 |
| | miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment | Q33864410 |
| | Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. | Q33985421 |
| | A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression | Q34020150 |
| | A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder | Q34026634 |
| | A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder | Q34031897 |
| | Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. | Q34088016 |
| | A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults | Q34172150 |
| | Oral scopolamine augmentation for major depression | Q34318539 |
| | Scopolamine as an antidepressant: a systematic review | Q34323471 |
| | A review of current evidence for vilazodone in major depressive disorder | Q34338647 |
| | Scopolamine and depression: a role for muscarinic antagonism? | Q34425303 |
| | Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder | Q34451408 |
| | Stress, depression, and neuroplasticity: a convergence of mechanisms | Q34686632 |
| | Is there a placebo problem in antidepressant trials? | Q36266281 |
| | The combination of duloxetine and bupropion for treatment-resistant major depressive disorder | Q36417858 |
| | 5-HT7, neurogenesis and antidepressants: a promising therapeutic axis for treating depression | Q36793918 |
| | No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis | Q37116846 |
| | An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder | Q37423561 |
| | Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression | Q37514703 |
| | Innovations in clinical research design and conduct in psychiatry: shifting to pragmatic approaches | Q37666548 |
| | New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. | Q37978196 |
| | Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants | Q38047714 |
| | Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia | Q38150488 |
| | Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? | Q38156001 |
| | The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder | Q38157024 |
| | Neurotransmitter targeting in the treatment of depression | Q38160077 |
| | Triple reuptake inhibitors: a patent review (2006 - 2012). | Q38167327 |
| | Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder | Q38200656 |
| | NMDA antagonists under investigation for the treatment of major depressive disorder | Q38211107 |
| | Vortioxetine for the treatment of major depressive disorder. | Q38244159 |
| | An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials | Q39445119 |
| | Neurobiological advances identify novel antidepressant targets | Q42685043 |
| | The well of novel antidepressants: running dry. | Q42739872 |
| | Does dual antidepressant therapy as initial treatment hasten and increase remission from depression? | Q43263646 |
| | A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine | Q43873749 |
| | A proposal for an updated neuropsychopharmacological nomenclature | Q44009538 |
| | Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study | Q44742910 |
| | A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition | Q45847558 |
| | Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation | Q46062036 |
| | A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment | Q48260359 |
| | Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. | Q48878233 |
| | Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. | Q53146596 |
| | The Serotonin Syndrome | Q55871784 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 445-453 | |
| P577 | publication date | 2014-12-20 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Criticisms of drugs in early development for the treatment of depression: what can be improved? | |
| P478 | volume | 24 | |